2 - 4 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
For more information, please view the literature below.
Red-top tube or gel-barrier tube
Separate serum from cells by centrifugation after clot formation.
Gross hemolysis; bacterial contamination; lipemia
An adjunct to β2-glycoprotein and anticardiolipins in diagnosing aPS (antiphospholipid syndrome) for assessing thrombotic risk and other obstetric complications such as miscarriage or fetal growth restriction
Enzyme-linked immunosorbent assay (ELISA)
Antiphospholipid antibodies are a heterogeneous group of immunoglobulins that bind to several anionic phospholipids, including cardiolipin and phosphatidylserine. High serum levels of antiphospholipid antibodies are frequently detected in patients with autoimmune (ie, SLE) and nonautoimmune diseases, as well as in apparently healthy individuals. These antibodies have been associated with an increased risk for recurrent arterial and venous thrombotic events, thrombocytopenia, and fetal loss. These manifestations are the main features of the antiphospholipid syndrome. Antiphospholipid antibodies are detected either by ELISAs using cardiolipin or other negatively-charged phospholipids as the antigen (anticardiolipin antibodies) or coagulation assays (lupus anticoagulants). Unlike cardiolipin, phosphatidylserine is a more physiologically relevant phospholipid due to its presence in cell membranes of endothelial cells and platelets and its role in the coagulation cascade. The detection of antiphosphatidylserine (aPS) antibodies by ELISA has been recommended for the serological diagnosis of antiphospholipid syndrome. Patients with positive reactions to both cardiolipin and phosphatidylserine are more likely to have clinical complications than those positive for only one. Higher prevalence and mean serum levels of antiphosphatidylserine antibodies have been reported in autoimmune patients. In addition, antiphosphatidylserine antibodies in SLE patients correlated with clinical manifestations of antiphospholipid syndrome and their pathogenic role has been demonstrated in a murine model.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|117994||Antiphosphatidylserine IgG/M/A||117910||Antiphosphatidylserine IgM||MPS IgM||14246-3|
|117994||Antiphosphatidylserine IgG/M/A||117926||Antiphosphatidylserine IgA||APS IgA||13069-0|
|117994||Antiphosphatidylserine IgG/M/A||117927||Antiphosphatidylserine IgG||GPS IgG||14245-5|
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf